MetaCap

Lisata Therapeutics (LSTA) vs China SXT Pharmaceuticals (SXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Lisata Therapeutics is the larger company by market cap ($647,451 vs $273,955), about 2.4 times the size, while China SXT Pharmaceuticals is growing revenue faster (-34.6% vs -83.0%). China SXT Pharmaceuticals converts more of its revenue into profit, with a net margin of -545.2% versus -9756.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LSTA-23.17%SXTC-6.54%
+36%-34%-105%
Oct 7, 20261 yearNov 20, 2026
LSTA-15.20%SXTC+1678.75%
+2194%+1007%-180%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LSTA versus SXTC key metrics
MetricLSTASXTC
Share price$0.8989$2.65
Market cap$647.45K$273.95K
1-day change-1.22%+2.12%
YTD return-51.67%—
1-year return-54.14%—
5-year return-93.89%—
EPS (TTM)$-28.20$-73,040.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$170.00K$1.14M
Revenue growth (YoY)-83.00%-34.63%
Net income (latest FY)$-16.59M$-6.21M
Gross margin—21.85%
Operating margin-10711.18%-625.89%
Net margin-9756.47%-545.24%
52-week high$76.05$8,376,000.00
52-week low$0.85$2.52
Distance from 52-week high-98.82%-100.00%
Analyst consensusnone—
Average volume13.46K234.25K
Shares outstanding720.27K103.58K
Employees2156
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Lisata Therapeutics is about 2.4 times larger than China SXT Pharmaceuticals by market value ($647.45K vs $273.95K).
  • China SXT Pharmaceuticals is more profitable, keeping -545.2 cents of every revenue dollar as net income versus -9756.5 cents for Lisata Therapeutics.
  • China SXT Pharmaceuticals grew revenue faster in its latest fiscal year (-34.63% vs -83.00%).

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About China SXT Pharmaceuticals

SXTC stock →

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

LSTA vs SXTC FAQ

Which is bigger, Lisata Therapeutics or China SXT Pharmaceuticals?

Lisata Therapeutics (LSTA) is larger, with a market capitalization of $647.45K compared with $273.95K for China SXT Pharmaceuticals (SXTC).

Are Lisata Therapeutics and China SXT Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons